安塔雷制药(纳斯达克：ATRS)获得StockNews.com分析师的卖出评级

Analysts at StockNews.com assumed coverage on shares of Antares Pharma (NASDAQ:ATRS – Get Rating) in a research report issued on Tuesday. The firm set a "sell" rating on the specialty pharmaceutical company's stock.

A number of other equities research analysts have also recently weighed in on the company. Raymond James cut Antares Pharma from a "strong-buy" rating to a "market perform" rating in a report on Thursday, April 14th. Truist Financial cut Antares Pharma from a "buy" rating to a "hold" rating and dropped their target price for the stock from $7.00 to $5.60 in a report on Wednesday, April 13th. Piper Sandler cut Antares Pharma from an "overweight" rating to a "neutral" rating and dropped their target price for the stock from $6.00 to $5.60 in a report on Thursday, April 14th. LADENBURG THALM/SH SH cut Antares Pharma from a "buy" rating to a "neutral" rating in a report on Thursday, April 14th. Finally, HC Wainwright cut Antares Pharma from a "buy" rating to a "neutral" rating and set a $5.60 target price on the stock. in a report on Thursday, April 14th. One research analyst has rated the stock with a sell rating and five have given a hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $5.60.

Get

Antares Pharma

alerts:

ATRS opened at $5.59 on Tuesday. The business's 50 day moving average is $5.58 and its 200-day moving average is $4.37. The stock has a market cap of $955.06 million, a PE ratio of 23.29 and a beta of 1.15. The company has a current ratio of 3.08, a quick ratio of 2.87 and a debt-to-equity ratio of 0.10. Antares Pharma has a twelve month low of $3.11 and a twelve month high of $5.60.

Antares Pharma (NASDAQ:ATRS – Get Rating) last released its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.01) earnings per share for the quarter. The business had revenue of $41.56 million for the quarter, compared to the consensus estimate of $44.01 million. Antares Pharma had a net margin of 21.90% and a return on equity of 7.43%. As a group, analysts forecast that Antares Pharma will post 0.08 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Walleye Capital LLC bought a new position in shares of Antares Pharma in the first quarter valued at $336,000. Rice Hall James & Associates LLC increased its holdings in shares of Antares Pharma by 0.6% in the first quarter. Rice Hall James & Associates LLC now owns 1,218,851 shares of the specialty pharmaceutical company's stock valued at $4,997,000 after buying an additional 7,500 shares in the last quarter. Jane Street Group LLC increased its holdings in shares of Antares Pharma by 10.8% in the first quarter. Jane Street Group LLC now owns 36,284 shares of the specialty pharmaceutical company's stock valued at $149,000 after buying an additional 3,535 shares in the last quarter. Douglass Winthrop Advisors LLC bought a new position in shares of Antares Pharma in the first quarter valued at $41,000. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Antares Pharma by 4.5% in the first quarter. Goldman Sachs Group Inc. now owns 1,191,359 shares of the specialty pharmaceutical company's stock valued at $4,885,000 after buying an additional 51,656 shares in the last quarter. 50.41% of the stock is currently owned by institutional investors.

About Antares Pharma (Get Rating)

Antares Pharma, Inc, a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems.

Further Reading

• Get a free copy of the StockNews.com research report on Antares Pharma (ATRS)
• Using MarketBeat Market Data Tools To Find Strong Stocks in a Bear Market
• Schnitzer Steel Witnesses A Strong Quarter On The Back Of Strong Domestic Demand
• MarketBeat: Week in Review 6/27 – 7/1
• Accolade Moves Higher But Growth Is Slowing
• ZIM Integrated Shipping Services (ZIM): Don't Miss This Dividend

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.